The Cracking Cancer Podcast

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by GI medical oncologist Dr. Chris Liu (University of Colorado Cancer Center) and Stage IV neuroendocrine rectal cancer patient advocate Bill Tutt. Bill brings an incredible, rare perspective—having navigated 11 lines of therapy and participated in 5 distinct clinical trials since his diagnosis in 2018.
Dr. Liu and Bill break down why clinical trials should be viewed as proactive options starting at diagnosis rather than as "last resorts." They demystify the multi-phase clinical trial pipeline, dispel common myths around "guinea pigs" or placebo controls, and highlight how trial participants gain access to FDA-approved therapies years ahead of the public. The panel also covers the essential role of comprehensive biomarker testing in colorectal and GI cancers—such as KRAS, DLL3, ATM, and Claudin—and highlights game-changing emerging modalities like Antibody-Drug Conjugates (ADCs), Radieligand/Radiopharmaceutical therapies, and homegrown CAR-T cell trials.
 
Key Takeaways:
Early Access Advantage
Debunking the Placebo Myth
The Three Essential Biomarker Questions
Sequencing Strategy Matters
Concierge Level of Monitoring
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
00:00 Welcome to Cracking Cancer
01:55 Bill’s Diagnosis Journey
05:42 When to Consider Trials
08:51 What Trials Really Are
14:07 Finding Trial Options
19:55 Second Opinions Matter
22:46 Trial Logistics and Tradeoffs
29:27 Trial Phases Explained
36:16 Choosing the Right Trial
39:25 Biomarkers in Colorectal Cancer
49:05 Future Therapies on the Horizon
52:54 Final Advice and Wrap Up
 
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

In this episode of Cracking Cancer, science communicator Rob Swanda, PhD, is joined by virologist and gene therapy researcher Dr. Cole Peters to pull back the curtain on the hidden mechanics of academic cancer funding in the United States. Dr. Peters walks listeners through the pipeline of National Institutes of Health (NIH) and National Cancer Institute (NCI) grants—from training awards to multi-year R01 research grants. He exposes the immense administrative burden and fierce competitiveness required to keep basic research labs alive.
The conversation explores the critical distinction between basic research (discovering fundamental biological processes) and translational research (moving lab findings to clinical trials), illustrating how iconic breakthroughs like PCR testing, Keytruda (PD-1 inhibitors), and CRISPR gene editing were all born out of basic research that initially had no direct clinical mandate. Dr. Peters also breaks down recent 2025–2026 administrative policy changes regarding grant funding structures and political oversight of peer review. He provides a stark, first-hand account of how grant freezes, "brain drain," and sudden funding interruptions disrupt mouse models, dismantle research teams, and set scientific momentum back by years.
 
Key Takeaways:
The Engine of American Innovation
Basic vs. Translational Research
The High Bar of Peer Review
Policy Shifts in Grant Oversight
The True Cost of Funding Delays
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
00:00 Welcome to Cracking Cancer01:41 Why Early Funding Matters02:11 How NIH Funding Works04:13 What Makes a Strong Grant11:01 Grant Success Rates and Competition15:33 Why Basic Research Matters18:34 Keytruda and PD-1 Origins23:52 How Grants Get Awarded27:35 Peer Review Changes and Risks33:38 Funding Cuts Hit Labs36:30 Brain Drain and Lost Momentum46:54 Basic Research Breakthroughs PCR50:30 State Funding and Local ROI52:55 Get Involved and Closing
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

In this solo episode of Cracking Cancer, patient advocate Samantha Murrell and science communicator Rob Swanda, PhD, dive into an unexpected topic in integrative oncology: the potential anti-cancer properties of statins—the most widely prescribed class of cardiovascular medications in the world. Driven by digital discussions around drug repurposing (similar to their recent exploration of GLP-1s), Samantha and Rob explore how cholesterol-lowering drugs might influence oncogenic signaling pathways and complement standard cancer therapies.
Rob breaks down the underlying biochemistry of statins, detailing how they block the HMG-CoA reductase enzyme. This mechanism not only reduces bad LDL cholesterol production but also cuts off the synthesis of isoprenoid lipids. These lipids act as essential molecular anchors that help key oncogenic driver proteins—such as RAS and Rho—attach to cell membranes and send downstream growth signals. The hosts contrast lipophilic versus hydrophilic statins, evaluate retrospective survival data in breast and lung cancer cohorts, and emphasize the critical importance of checking for drug-drug interactions and genetic variants (like the SLCO1B1 transporter gene) before modifying any medication regimen.
 
Key Takeaways:
Beyond Cholesterol Reduction
The Lipophilic vs. Hydrophilic Difference
Biomarker Overlaps (HER2 & EGFR)
The Danger of Pharmacogenomic Toxicity
Association Is Not Causation
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Want to read the papers disussed in this episode yourself? Links are below!
https://pmc.ncbi.nlm.nih.gov/articles/PMC11912801/
https://www.sciencedirect.com/science/article/abs/pii/S1933287423001630?utm_source=copilot.com
https://pmc.ncbi.nlm.nih.gov/articles/PMC12170056/
 
 
Chapters:
00:00 Welcome and Mission01:10 Why Statins and Cancer02:01 Cholesterol and Statins 10104:24 Other Cholesterol Drugs06:50 Statins Bad Rap12:06 Mevalonate Pathway and Cancer15:13 HER2 EGFR Connections18:34 What the Studies Show27:37 Why Papers Say More Research30:31 Drug Interactions and Dosing34:04 Genetics and Statin Response41:31 Wrap Up and Next Topics42:29 Outro and Support the Show
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

In this eye-opening episode of Cracking Cancer, host Dr. Kyle Concannon is joined by Max Doppelt, founder of Patient Data Vault, to tackle one of the most frustrating aspects of modern oncology: clinical trial exclusion criteria. Max shares the heartbreaking story of his mother, who was diagnosed with EGFR Exon 20 non-small cell lung cancer (NSCLC). After weeks of agonizing screening to access a promising targeted trial, she was rejected over subtle CT scan findings that hinted at—but did not confirm—pneumonitis. That screening failure forced their family to travel to China to obtain a life-saving drug that was not yet accessible to her in the United States.
Dr. Kyle and Max dissect the hidden mechanics of clinical trial design, explaining why trials are often risk-averse, hyper-rigorous experiments designed to isolate variables for FDA approval rather than accommodate real-world complexity. The panel exposes common pitfalls that screen-fail patients—from active brain metastases and strict ECOG performance scores to the "first-line trap," where receiving a single dose of standard chemotherapy permanently disqualifies a patient from frontline trials. They also address "time toxicity"—the dangerous weeks lost in administrative limbo while a patient's cancer progresses—and highlight how platforms like Patient Data Vault use AI to bring total protocol transparency to patients before they waste critical time.
 
Key Takeaways:
The "First-Line" Trap
ECOG Performance Status is Dynamic
Brain Metastases Risk-Aversion
The High Cost of "Time Toxicity"
The US vs. EU Protocol Transparency Gap
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
00:00 Welcome to Cracking Cancer00:59 Meet Max Doppelt01:20 A Trial Rejection Story04:36 Why Exclusion Criteria Exist06:40 Pneumonitis Gray Areas09:58 Common Trial Dealbreakers11:04 Brain Mets and Delays16:29 Lines of Therapy Trap18:56 Finding Frontline Trials23:59 ECOG Performance Status34:25 Labs and Modifiable Factors36:32 Screening Delays and Retesting42:33 Protocol Design and Copy Paste45:25 Transparency and AI Tools55:12 Patient Support and Advocacy59:37 Final Takeaways and Resources
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

The Ethics and Impacts of Clinical Trial Prediction Markets
In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by patient advocate Samantha Murrell and science communicator Rob Swanda, PhD, to tackle an unforeseen intersection in modern medicine: the rise of prediction markets on clinical trial outcomes. The panel dissects the recent introduction of prediction markets for FDA regulatory approvals and Phase 3 trial endpoints—including progression-free survival (PFS) and overall survival (OS).
The team explores the severe moral and psychological ramifications of treating life-saving medical research like a sports wager. Samantha shares the distressing reality for cancer patients facing a Phase 3 trial, who may now see public financial markets actively "b*****g against" their treatment's success. Dr. Kyle and Rob analyze how these speculative markets risk introducing profound biases into clinical trial measurements, threatening patient enrollment, compromising investigator objectivity, and reducing complex biological discoveries down to binary, short-term financial wagers.
 
Key Takeaways:
The Arrival of Clinical Trial Prediction Markets
The Psychological Toll on Enrolled Patients
Unconscious Bias in Scan Measurement
Erosion of Scientific Nuance
Ethical and Insider Trading Vulnerabilities
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
00:00 B*****g On Trials02:47 Patient Advocate Reaction05:03 Hope And Harm09:24 Endpoints Explained11:25 How Trial Data Forms12:40 Bias And Measurement17:29 Insider Info Risks25:01 Threats And Coercion39:04 Negative Trials Still Help47:57 Symptom Bias And Reporting59:07 Better Things To B** On
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by GI medical oncologist Dr. Sam Klempner (Mass General Brigham) and Stage IV gastric cancer patient advocate Frank Blandon. Frank shares his journey of navigating a diagnostic whirlwind—from being initially misdiagnosed with testicular cancer to finding that a "collapsed stomach" on CT scans hid the true primary tumor.
Dr. Klempner breaks down the biology of gastric and gastroesophageal junction (GEJ) cancers, explaining how chronic inflammation (from sources like H. pylori or Epstein-Barr Virus) can spark mutations. The panel explores the rapidly expanding biomarker landscape—including PD-L1, HER2, MSI/MMR, and Claudin 18.2—and why getting comprehensive testing upfront is vital for matching patients to modern immunotherapies, antibody-drug conjugates (ADCs), and clinical trials. They also address the psychological hurdles of seeking a second opinion and why "stage is just a number" in an era of transformative treatments.
 
Key Takeaways:
Vague Early Symptoms Lead to Delays
The Four Essential Biomarkers
EBV-Associated Gastric Cancer
Managing "Time Toxicity" and Treatment Regimens
Second Opinions Are Not Insults (MOST IMPORTANT)
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
(00:00) Meet The Guests
(02:48) Frank Misdiagnosis Story
(07:02) Symptoms And Early Clues
(09:07) Risk Factors And Causes
(12:03) EBV And Anemia Explained
(14:49) Biomarkers That Guide Care
(22:05) Frank Treatment Journey
(24:48) Managing Side Effects
(27:28) Stage Based Treatment Options
(31:59) Trials And New Therapies
(37:04) Hope From Research And ASCO
(39:01) Support Groups And Advocacy
(41:09) Second Opinions Matter
(47:57) Final Advice And Wrap Up
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by Jeanne Zurek, a Stage IV EGFR-mutated non-small cell lung cancer patient from Minnesota, and science communicator Rob Swanda, PhD. The episode focuses on how the route of drug administration impacts a patient's quality of life, moving from oral TKIs to intravenous (IV) infusions and, ultimately, to subcutaneous (SubQ) injections.
Jeanne shares their personal experience transitioning from hours-long IV infusions of amivantamab—which frequently triggered infusion reactions and required heavy steroid pre-medications—to a 5-minute SubQ injection. Rob explains the underlying biochemistry of this transition, highlighting how formulation innovations like hyaluronidase break down tissue barriers to allow larger drug volumes under the skin. Together with Dr. Kyle, they discuss the reduction of "time toxicity," how shorter administration times increase infusion clinic capacity for newly diagnosed patients, and the future of long-acting injectables and home-based cancer care.
 
Key Takeaways:
The Shift from IV to SubQ
The Role of Hyaluronidase
Reduction in Infusion Reactions
Mitigating "Time Toxicity"
Systemic Clinic Benefits
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
(00:00) Meet the Guests
(02:22) Jeanne’s Diagnosis Journey
(04:26) From Pills to Antibodies
(06:03) Routes of Administration 101
(07:36) IV Infusion Reality Check
(10:06) Managing Infusion Reactions
(15:14) Switching to SubQ Injections
(24:26) SubQ Benefits and Time Toxicity
(30:48) How SubQ Delivery Works
(37:55) Side Effects and Patient Advocacy
(48:12) Future Delivery and Clinic Capacity
(54:05) Pills vs Long Acting Options
(58:39) Wrap Up and Next Steps
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

The Metabolic Blueprint: Weighing the Evidence on GLP-1s and Cancer Survival
In this highly anticipated episode of Cracking Cancer, host Dr. Kyle Concannon sits down with patient advocate Samantha Murrell and science communicator Rob Swanda, PhD, to tackle the most talked-about presentation from the 2026 American Society of Clinical Oncology (ASCO) annual meeting: the intersection of GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Mounjaro) and oncology. Samantha reveals that she has been using an off-label microdose of a GLP-1 alongside her targeted therapy for Stage IV HER2-mutant lung cancer, not for weight loss, but to target systemic, chronic inflammation.
The trio breaks down large-scale real-world data tracking over 25,000 patients, which uncovered a striking associative signal: patients taking GLP-1s alongside traditional targeted therapies were twice as likely to be alive at five years compared to matched cohorts. Dr. Kyle and Rob dissect what this means from a biochemical perspective. They separate mere association from actual causation, explore why chronic inflammation can act as a shield for tumors, and detail the strict clinical rules patients must follow—such as preserving lean muscle mass to prevent cachexia—if they choose to discuss these metabolically active compounds with their oncology teams.
 
Key Takeaways:
The Staggering ASCO Survival Signal
Chronic Inflammation vs. Acute Immune Response
The Metformin Connection
The Critical Muscle Mass Warning
The "Healthy Baseline" Confounder
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
(00:00) Sugar Feeds Cancer(01:57) Why GLP-1s Are Buzzing(05:15) Association vs Causation(07:06) Patient Concerns and Anecdotes(10:54) Inflammation Theory and ASCO Data(15:22) Evidence Review and Metformin Link(21:12) Glucose Control Mythbusting(28:00) What GLP-1 Drugs Are(30:36) Next Gen GLP-1s(31:31) Long Acting and Oral Options(32:07) ASCO Lung Cancer Signal(36:23) Interpreting Retrospective Data(39:13) Why Samantha Tried It(40:14) Absorption Theory and Dosing(41:28) Early Side Effects and Adaptation(43:01) Microdosing Caveats(45:14) Autoimmune and Histamine Effects(50:55) Broader Cancer Survival Data(53:35) Practical Safety Guidance(56:34) What We Still Dont Know
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

In this special behind-the-scenes episode of Cracking Cancer, host Dr. Kyle Concannon sits down for a candid, scientist-to-scientist conversation with science communicator Rob Swanda, PhD. Stepping away from the traditional patient-interview format, Kyle and Rob pull back the curtain on their own medical paths to explore a profound systemic challenge: the widening chasm between complex oncology research and the everyday patient.
Rob shares his viral origin story, which began during his doctoral work at Cornell studying mRNA therapeutics for kidney cancer. When the pandemic hit, a simple explanatory video made for his own family skyrocketed into a full-time mission to demystify laboratory science. Kyle shares a deeply personal, never-before-told story about growing up in a low-healthcare-literacy household in rural Vermont, navigating his brother’s rare genetic liver disorder, and the decades of silent anxiety his mother carried simply because she lacked the vocabulary to ask her doctors the right questions. Together, they deconstruct the broken incentives of modern academic publishing, the flaws of the journal "impact factor" business, and how breaking down elitist medical jargon empowers patients to reclaim control over their own clinical destinies.
 
Key Takeaways:
The Widening Scientific Chasm
The "Whiteboard" Anchor for Clinical Care
The Fragmented Reality of Learning
The Business of the Peer-Review "Paywall"
Empathy as a Clinical Metric
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
Chapters:
(00:00) Welcome to Cracking Cancer
(00:22) Why Those mRNA Videos Took Off
(09:55) How to Explain Complex Science
(13:35) Empowering Patients and Caregivers
(18:37) Many Ways to Communicate Science
(23:08) Finding Credible Information
(25:09) Peer Review and Impact Factor
(35:05) AI as a Learning Tool
(40:22) Kyle’s Personal Why
(50:42) Advice and Wrap Up
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

Deconstructing Fenbendazole: Scaffolding, Solvents, and the "Joe Tippens" Protocol
In this highly requested follow-up to their Ivermectin discussion, host Dr. Kyle Concannon, patient advocate Samantha Murrell, and science communicator Rob Swanda, PhD, touch the hot stove of alternative oncology once again. This time, they dive deep into Fenbendazole (commonly called "Fenben"), an antiparasitic veterinary drug that has exploded in popularity across cancer forums due to the viral "Joe Tippens Protocol." Samantha opens up about her personal choice to take Fenbendazole secretly for eight months alongside conventional chemotherapy, providing an unfiltered look at the immense "what if" pressure patients face behind closed doors.
The conversation shifts to rigorous biochemical scrutiny as Dr. Kyle and Rob break down what the drug actually does inside a petri dish and a living organism. They expose the fascinating irony of alternative health branding: while Fenbendazole is frequently marketed online as a "natural, holistic alternative to harsh toxins," it is completely synthetic. Conversely, the very chemotherapies it seeks to replace are the ones derived directly from nature. Moving step-by-step through peer-reviewed data, they analyze how this compound disrupts cellular architecture, why its therapeutic thresholds carry hidden toxicities, and how missing variables in animal models can obscure the difference between a true anti-tumor signal and a general cellular poison.
 
Key Takeaways:
The Microtubule Mechanism (Chemo in Disguise)
The P53 Gene Context
The "Healthy Tissue" Toxicity Flaw
Flawed Mouse Models & Missing Data
Association vs. Causation
 
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Giving.CU.EDU/CrackingCancer 
 
For more information on Fenbendazole, check out Rob's info-packed video below!
https://youtu.be/DDVko6G84wo
 
Want to see the data yourself? Check out the actual papers below:
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
https://pmc.ncbi.nlm.nih.gov/articles/PMC6085345/
Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma
https://www.mdpi.com/1467-3045/45/11/560 
 
Chapters:
(00:00) Why Fenbendazole Now
(01:38) Samantha Tries Fenben
(02:09) Joe Tippens Protocol Buzz
(04:04) How She Took It
(06:14) Social Pressure and Disclosure
(08:23) What Fenbendazole Is
(11:17) Microtubules and Cancer Logic
(13:29) Natural Versus Synthetic Debate
(17:25) Preclinical Evidence Deep Dive
(19:31) Mouse Study Caveats
(25:57) Safety Unknowns and Next Steps
(30:39) Paper Rigor Check
(31:42) Dose Response Reality
(33:15) P53 Dependency Explained
(38:25) Healthy Cell Toxicity
(40:32) Missing Controls Bias
(42:28) Second Study Lymphoma
(44:42) Why Immune Free Mice
(49:30) How Strong Is Evidence
(54:38) Anecdotes Versus Causation
(57:00) Mechanism Gaps Takeaways
(59:33) Final Verdict Sign Off
 
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
 
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
 
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos